Using high-throughput RNA interference (RNAi) kinome library screening, reverse phase protein array (RPPA), and conventional in vitro and in vivo preclinical models, we tested our hypothesis that neratinib with rational combination therapy can induce effective anti-tumor activity in both HER2+ breast cancer and TNBC. Here, ERBB2 is linked to breast cancer.